Abstract
To the Editor. —The findings of Soumerai et al 1 lump all calcium channel blockers into one group. While no calcium channel blocker is currently approved by the Food and Drug Administration for prevention of morbidity and mortality post-MI, data from several studies have shown that verapamil can reduce morbidity and mortality in some post-MI patients. The Second Danish Verapamil Infarction Trial (DAVIT II) 2,3 randomized patients (
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call